FDA Has Accepted For Priority Review Ionis Pharmaceuticals' New Drug Application For Olezarsen For Familial Chylomicronemia Syndrome, With FDA Action Date Of December 19
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Ionis Pharmaceuticals' New Drug Application for Olezarsen, a treatment for Familial Chylomicronemia Syndrome, for priority review. The FDA action date is set for December 19.
June 25, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA has accepted Ionis Pharmaceuticals' New Drug Application for Olezarsen for priority review, indicating a potentially faster approval process. The FDA action date is December 19.
The acceptance of the NDA for priority review suggests that the FDA sees significant potential in Olezarsen, which could lead to a faster approval process. This is a positive development for Ionis Pharmaceuticals, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100